Spectrum Pharmaceuticals announces FDA approval of Fusilev's Ready-To-Use formulation (RTU).

Spectrum Pharmaceuticals (Spectrum) announced that the US Food and Drug Administration (FDA) has approved the company's Supplemental New Drug Application for Fusilev (levoleucovorin) Injection. Unlike the currently available lyophilised product, this approval is for a 'Ready-to-Use' formulation of Fusilev (levoleucovorin) for Injection. Fusilev (levoleucovorin) for Injection is currently FDA approved and marketed by Spectrum for rescue after high-dose methotrexate therapy in osteosarcoma. Fusilev …